Sign In to Request a Protocol
Sign In to Request a Protocol

AOD-9604 + CJC-1295 + Ipamorelin Research Overview

  • Table of Contents

AOD-9604 + CJC-1295 + Ipamorelin Research Summary

This section provides general scientific information related to AOD-9604, CJC-1295, and Ipamorelin research. No Research Information, preparation, Research Procedure, or administration guidance is provided.

  • Vial contents: 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin (12 mg total).
  • Research Preparation Information: Add 3.0 mL bacteriostatic water → 4 mg/mL total (2 mg/mL AOD, 1 mg/mL CJC, 1 mg/mL lp).
  • Typical daily range: 0.1-0.2 mL once daily (200-400 mcg AOD / 100-200 mcg CJC / 100-200 mcg Ip).
  • Easy measuring: At 4 mg/mL total, 1 unit = 0.01 mL = 40 mcg total (20 mcg AOD + 10 mcg CJC + 10 mcg lp).
  • Storage: Lyophilized: freeze at -20 °C (-4 °F); after Research Preparation Information, refrigerate at 2-8 °C (35.6-46.4 °F); avoid freeze-thaw cycles.

This synergistic blend combines three peptides targeting body composition: AOD-9604 (hGH fragment 177-191) promotes lipolysis without raising IGF-1 CJC-1295 (GHRH analog) produces sustained GH and IGF-1 elevations and Ipamorelin (ghrelin mimetic) selectively stimulates GH secretion without increasing cortisol or ACTH, Together, these peptides may support lean mass gains and fat reduction.

  • Research Information Guide

Educational guide for Research Preparation Information and daily dosing

Research Study Considerations

Research Characteristics : 2.0 mg/mL AOD-9604 | 1.0 mg/mL CJC-1295 | 1.0 mg/mL Ipamorelin

Research TimelineResearch ParametersResearch Measurement
Week 1200 mcg AOD / 100 mcg CJC / 100 mcg Ip10 units (0.10 mL)
Week 2300 mcg AOD / 150 mcg CJC / 150 mcg Ip15 units (0.15 mL)
Weeks 3–12400 mcg AOD / 200 mcg CJC / 200 mcg Ip20 units (0.20 mL)
Frequency: Inject once daily subcutaneously, preferably in the morning or before bed on an empty stomach. For ≤10‑unit (≤0.10 mL) administrations during titration, consider 30‑ or 50‑unit insulin syringes for improved readability.
Laboratory Research Considerations
  • 1 . Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2 . Inject slowly down the vial wall; avoid foaming.
  • 3 . Gently swirl/roll until dissolved (do not shake).
  • 4 . Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Research Measurement Considerations

Using a U-100 insulin syringe (100 units = 1 mL):

  • 1 unit (0.01 mL) = 20 mcg AOD + 10 mcg CJC + 10 mcg Ip
  • 10 units (0.10 mL) = 200 mcg AOD + 100 mcg CJC + 100 mcg Ip
  • 15 units (0.15 mL) = 300 mcg AOD + 150 mcg CJC + 150 mcg Ip
  • 20 units (0.20 mL) = 400 mcg AOD + 200 mcg CJC + 200 mcg Ip

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Research Requirements

Plan based on an 8–16 week daily protocol with gradual titration (maintenance dose: 0.20 mL/day).

  • Peptide Blend Vials (12 mg each):
  • 8 weeks (~11.2 mL total): 4 vials
  • 12 weeks (~16.8 mL total): 6 vials
  • 16 weeks (~22.4 mL total): 8 vials
  • Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for Research Preparation.
  • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the Research Procedure site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Research Overview

Concise summary of the once‑daily regimen.

  • Goal: Support body composition improvements through combined lipolytic and GH-stimulating mechanisms.
  • Schedule: Daily subcutaneousResearch Procedure for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip daily with gradual titration.
  • Research Preparation Information: 3.0 mL per 12 mg vial (4 mg/mL total concentration).
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Research Applications

Suggested daily titration approach.

  • Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip); increase by ~0.05 mL weekly as tolerated.
  • Target: 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ip) by Week 3.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Morning or before bed on an empty stomach; rotateResearch Procedure sites.
  • Material Handling Considerations

Proper storage preserves peptide quality.

  • Lyophilized: Store at –20 °C (–4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days per CDC/USP guidelines.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Research Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each Research Procedure dispose in a sharps container.
  • Rotate Research Procedure sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Best administered on an empty stomach (fasting) for optimal GH release.
  • How This Works

This blend combines three complementary peptides with distinct mechanisms:

  • AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism.
  • CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels, supporting anabolic processes and fat metabolism.
  • Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol, offering a cleaner GH release profile.

Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy.

  • Research Findings & Limitations

Observations from preclinical and clinical literature.

Potential Benefits

  • Supports reduction in fat mass and enhancement of lipolysis.
  • May promote lean mass gains through sustained GH and IGF-1 elevation.
  • Selective GH release without significant cortisol or prolactin increases.
  • AOD-9604 shows a placebo-like safety profile in human studies.

Possible Side Effects

  • Mild Research Procedure-site reactions (redness, itching) with subcutaneous administration.
  • Transient flushing or warmth following Research Procedure..
  • Occasional headache or lightheadedness during initial use.
  • Water retention (typically mild) with sustained GH elevation.
  • Related Research Considerations

Complementary strategies for best outcomes.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize quality sleep (7–9 hours) to maximize endogenous GH release.
  • Manage stress to optimize hormonal balance and recovery.
  • Stay hydrated and maintain consistent meal timing.
  • Research Procedure Information

General subcutaneous guidance from clinical best-practice resources.

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous Research Procedure; inject slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
  • Dispose of used syringes in an approved sharps container; follow local disposal regulations.
  • Research Resources

We recommend Vitality Labs Peptides for high-purity AOD-9604 + CJC-1295 + Ipamorelin Blend (12 mg).

About Vitality Labs Research ?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Research Disclaimer
This content is intended for  therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
  • References

Journal of Endocrinology & Metabolism (2014)

— Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health
More Info

Journal of Clinical Endocrinology & Metabolism (PubMed)

— Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
More Info

European Journal of Endocrinology (PubMed)

— Ipamorelin: the first selective growth hormone secretagogue
More Info

Translational Andrology and Urology (PMC)

— Role of growth hormone secretagogues in body composition management
More Info

Endocrinology (OUP)

— hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights
More Info

CDC

— Preventing unsafe Research Procedure practices: multi-dose vial handling guidelines
More Info

Journal of Endocrinology & Metabolism (2013)

— Safety and tolerability of the hexadecapeptide AOD9604 in humans
More Info

Obesity Pharmacotherapy Review (PMC)

— AOD-9604 clinical trial overview and weight loss outcomes
More Info

Subcutaneous Drug Research Procedure Review (PMC)

— Pharmacologic considerations of the subcutaneous route
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site guidance)
More Info

MedlinePlus

— Subcutaneous Research Procedure: patient instructions and technique
More Info

NCBI Bookshelf

— Best practices for Research Procedure asepsis, preparation, and administration
More Info

Central & Peripheral Anti-Obesity Targets (PMC)

— AOD-9604 RCT summary and mechanistic overview
More Info

PubMed

— Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation)
More Info

Vitality Labs Peptides

— AOD-9604 + CJC-1295 + Ipamorelin Blend product page (quality and batch documentation)
More Info
  • Table of Contents

AOD-9604 + CJC-1295 + Ipamorelin Dosage Chart

The AOD-9604 + CJC-1295 + Ipamorelin peptide blend is dosed at 200 mcg–400 mcg daily via subcutaneous injection in educational protocols. A 12 mg blend reconstituted with bacteriostatic water yields about 4 mg/mL. This information is for research and educational use only.

  • Vial contents: 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin (12 mg total).
  • Reconstitute: Add 3.0 mL bacteriostatic water → 4 mg/mL total (2 mg/mL AOD, 1 mg/mL CJC, 1 mg/mL lp).
  • Typical daily range: 0.1-0.2 mL once daily (200-400 mcg AOD / 100-200 mcg CJC / 100-200 mcg Ip).
  • Easy measuring: At 4 mg/mL total, 1 unit = 0.01 mL = 40 mcg total (20 mcg AOD + 10 mcg CJC + 10 mcg lp).
  • Storage: Lyophilized: freeze at -20 °C (-4 °F); after reconstitution, refrigerate at 2-8 °C (35.6-46.4 °F); avoid freeze-thaw cycles.

This synergistic blend combines three peptides targeting body composition: AOD-9604 (hGH fragment 177-191) promotes lipolysis without raising IGF-1[1]; CJC-1295 (GHRH analog) produces sustained GH and IGF-1 elevations [2]; and Ipamorelin (ghrelin mimetic) selectively stimulates GH secretion without increasing cortisol or ACTH [3], Together, these peptides may support lean mass gains and fat reduction[4].

  • Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL reconstitution)

Concentration after reconstitution: 2.0 mg/mL AOD-9604 | 1.0 mg/mL CJC-1295 | 1.0 mg/mL Ipamorelin
Research TimelineResearch ParametersResearch Measurement
Week 1200 mcg AOD / 100 mcg CJC / 100 mcg Ip10 units (0.10 mL)
Week 2300 mcg AOD / 150 mcg CJC / 150 mcg Ip15 units (0.15 mL)
Weeks 3–12400 mcg AOD / 200 mcg CJC / 200 mcg Ip20 units (0.20 mL)
Frequency: Inject once daily subcutaneously, preferably in the morning or before bed on an empty stomach. For ≤10‑unit (≤0.10 mL) administrations during titration, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  • 1 . Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2 . Inject slowly down the vial wall; avoid foaming.
  • 3 . Gently swirl/roll until dissolved (do not shake).
  • 4 . Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Syringe Math Reference

Using a U-100 insulin syringe (100 units = 1 mL):

  • 1 unit (0.01 mL) = 20 mcg AOD + 10 mcg CJC + 10 mcg Ip
  • 10 units (0.10 mL) = 200 mcg AOD + 100 mcg CJC + 100 mcg Ip
  • 15 units (0.15 mL) = 300 mcg AOD + 150 mcg CJC + 150 mcg Ip
  • 20 units (0.20 mL) = 400 mcg AOD + 200 mcg CJC + 200 mcg Ip

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration (maintenance dose: 0.20 mL/day).

  • Peptide Blend Vials (12 mg each):
  • 8 weeks (~11.2 mL total): 4 vials
  • 12 weeks (~16.8 mL total): 6 vials
  • 16 weeks (~22.4 mL total): 8 vials
  • Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support body composition improvements through combined lipolytic and GH-stimulating mechanisms.
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip daily with gradual titration.
  • Reconstitution: 3.0 mL per 12 mg vial (4 mg/mL total concentration).
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Dosing Protocol

Suggested daily titration approach.

  • Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip); increase by ~0.05 mL weekly as tolerated.
  • Target: 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ip) by Week 3.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Morning or before bed on an empty stomach; rotate injection sites.
  • Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at –20 °C (–4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days per CDC/USP guidelines.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Best administered on an empty stomach (fasting) for optimal GH release.
  • How This Works

This blend combines three complementary peptides with distinct mechanisms:

  • AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism.
  • CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels, supporting anabolic processes and fat metabolism.
  • Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol, offering a cleaner GH release profile.

Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy.

  • Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

Potential Benefits

  • Supports reduction in fat mass and enhancement of lipolysis.
  • May promote lean mass gains through sustained GH and IGF-1 elevation.
  • Selective GH release without significant cortisol or prolactin increases.
  • AOD-9604 shows a placebo-like safety profile in human studies.

Possible Side Effects

  • Mild injection-site reactions (redness, itching) with subcutaneous administration.
  • Transient flushing or warmth following injection.
  • Occasional headache or lightheadedness during initial use.
  • Water retention (typically mild) with sustained GH elevation.
  • Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize quality sleep (7–9 hours) to maximize endogenous GH release.
  • Manage stress to optimize hormonal balance and recovery.
  • Stay hydrated and maintain consistent meal timing.
  • Injection Technique

General subcutaneous guidance from clinical best-practice resources.

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
  • Dispose of used syringes in an approved sharps container; follow local disposal regulations.
  • Recommended Source

We recommend Vitality Labs Peptides for high-purity AOD-9604 + CJC-1295 + Ipamorelin Blend (12 mg).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note
This content is intended for  therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
  • References

Journal of Endocrinology & Metabolism (2014)

— Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health
More Info

Journal of Clinical Endocrinology & Metabolism (PubMed)

— Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
More Info

European Journal of Endocrinology (PubMed)

— Ipamorelin: the first selective growth hormone secretagogue
More Info

Translational Andrology and Urology (PMC)

— Role of growth hormone secretagogues in body composition management
More Info

Endocrinology (OUP)

— hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights
More Info

CDC

— Preventing unsafe injection practices: multi-dose vial handling guidelines
More Info

Journal of Endocrinology & Metabolism (2013)

— Safety and tolerability of the hexadecapeptide AOD9604 in humans
More Info

Obesity Pharmacotherapy Review (PMC)

— AOD-9604 clinical trial overview and weight loss outcomes
More Info

Subcutaneous Drug Injection Review (PMC)

— Pharmacologic considerations of the subcutaneous route
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site guidance)
More Info

MedlinePlus

— Subcutaneous injections: patient instructions and technique
More Info

NCBI Bookshelf

— Best practices for injection: asepsis, preparation, and administration
More Info

Central & Peripheral Anti-Obesity Targets (PMC)

— AOD-9604 RCT summary and mechanistic overview
More Info

PubMed

— Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation)
More Info

Vitality Labs Peptides

— AOD-9604 + CJC-1295 + Ipamorelin Blend product page (quality and batch documentation)
More Info
  • Related Dosage Protocols

Explore related research dosage protocols and background reading for AOD-9604 + CJC-1295 + Ipamorelin.

 

Ipamorelin (5 mg Vial) Dosage Protocol

Ipamorelin (10 mg Vial) Dosage Protocol

AOD-9604 (2 mg Vial) Dosage Protocol

AOD-9604 (5 mg Vial) Dosage Protocol